News
Shareholder interview with AcouSort’s CEO Torsten Freltoft and Commercial Director Agnes Michanek
Read more about AcouSort’s ongoing collaborations within cell therapy as well as other focus areas for 2024 in the...
Read MoreInterim Report Q4 2023
RegulatoryToday, AcouSort releases its interim report for Q4 2023. The report can be found in both Swedish and English...
Read MoreAcouSort presents at RedEye Regenerative medicine/ Cell Therapy event
AcouSort’s CEO Torsten Freltoft presents at RedEye Regenerative medicine/ Cell Therapy event in Stockholm February 14 2024. Follow the...
Read MoreShareholder interview with AcouSort’s CEO Torsten Freltoft and Commercial Director Agnes Michanek
Read more about AcouSort’s ongoing collaborations within cell therapy as well as other focus areas for 2024 in the...
Read MoreInterim Report Q4 2023
RegulatoryToday, AcouSort releases its interim report for Q4 2023. The report can be found in both Swedish and English...
Read MoreSignificant technical progress in the AcouSome project – two novel patent applications filed
In August 2022, the European Innovation Council (EIC) awarded the AcouSort project AcouSome SEK 26 million to develop groundbreaking...
Read MoreAcouSort presents at RedEye Regenerative medicine/ Cell Therapy event
AcouSort’s CEO Torsten Freltoft presents at RedEye Regenerative medicine/ Cell Therapy event in Stockholm February 14 2024. Follow the...
Read MoreAcouSort presents at BioStock Life Science Summit October 26
Read more: https://www.biostock.se/biostock-life-science-fall-summit-2023/.
Read MoreCEO Torsten Freltoft presents AcouSort’s opportunities in cell therapy and diagnostics at LSX Nordic Congress on October 10
AcouSort is an innovative medical technology company developing critical components for instrumentation used in the diagnostics, analytics, and cell...
Read More